The deal brings Exact Sciences' flagship screening test for colorectal cancer, Cologuard, under Abbott's umbrella.

Abbott closes $21B acquisition of Exact Sciences (EXAS) at $105/share. EXAS delisted from Nasdaq on March 23, 2026, becoming ...

Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.

Abbott Laboratories (NYSE:ABT) is one of the Best Conservative Stocks to Buy Right Now. On March 23, the company announced that it had completed the acquisition of Exact Sciences. As a result of this, ...

Abbott (NYSE:ABT) announced today that it completed its acquisition of cancer diagnostics developer Exact Sciences.

Abbott (NYSE: ABT) announced today that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.

View Exact Sciences Corporation EXAS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% ...

MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth ...

Exact Sciences Corp. research and ratings by Barron's. View EXAS revenue estimates and earnings estimates, as well as ...